Report cover image

Global Oligonucleotides Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Jul 16, 2025
Length 204 Pages
SKU # APRC20283897

Description

Summary

According to APO Research, The global Oligonucleotides market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Oligonucleotides is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Oligonucleotides is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Oligonucleotides is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Oligonucleotides is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Oligonucleotides include Agilent, BBI Life Sciences, Creative Biogene, Eurofins Genomics, Eurogentec S.A, GeneDesign, General Biosystems, GenScript and Integrated DNA Technologies, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Oligonucleotides, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Oligonucleotides, also provides the revenue of main regions and countries. Of the upcoming market potential for Oligonucleotides, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Oligonucleotides revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Oligonucleotides market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Oligonucleotides revenue, projected growth trends, production technology, application and end-user industry.

Oligonucleotides Segment by Company

Agilent
BBI Life Sciences
Creative Biogene
Eurofins Genomics
Eurogentec S.A
GeneDesign
General Biosystems
GenScript
Integrated DNA Technologies
L.G.C Biosearch Technologies
LC Sciences
Nitto Denko Avecia Inc
SGS DNA
Sigma-aldrich
TriLink BioTechnologies
Twist Bioscience
Oligonucleotides Segment by Type

DNA
RNA
Oligonucleotides Segment by Application

Gene Chip
Fluorescence In Situ Hybridization
Electrophoresis
Oligonucleotides Segment by Region

North America
United States
Canada
Europe

Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific

China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America

Mexico
Brazil
Argentina
Middle East & Africa

Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oligonucleotides market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oligonucleotides and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oligonucleotides.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Oligonucleotides in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Oligonucleotides company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oligonucleotides revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

204 Pages
1 Market Overview
1.1 Product Definition
1.2 Oligonucleotides Market by Type
1.2.1 Global Oligonucleotides Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 DNA
1.2.3 RNA
1.3 Oligonucleotides Market by Application
1.3.1 Global Oligonucleotides Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Gene Chip
1.3.3 Fluorescence In Situ Hybridization
1.3.4 Electrophoresis
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Oligonucleotides Market Dynamics
2.1 Oligonucleotides Industry Trends
2.2 Oligonucleotides Industry Drivers
2.3 Oligonucleotides Industry Opportunities and Challenges
2.4 Oligonucleotides Industry Restraints
3 Global Growth Perspective
3.1 Global Oligonucleotides Market Perspective (2020-2031)
3.2 Global Oligonucleotides Growth Trends by Region
3.2.1 Global Oligonucleotides Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Oligonucleotides Market Size by Region (2020-2025)
3.2.3 Global Oligonucleotides Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Oligonucleotides Revenue by Players
4.1.1 Global Oligonucleotides Revenue by Players (2020-2025)
4.1.2 Global Oligonucleotides Revenue Market Share by Players (2020-2025)
4.1.3 Global Oligonucleotides Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Oligonucleotides Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Oligonucleotides Key Players Headquarters & Area Served
4.4 Global Oligonucleotides Players, Product Type & Application
4.5 Global Oligonucleotides Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Oligonucleotides Market CR5 and HHI
4.6.3 2024 Oligonucleotides Tier 1, Tier 2, and Tier 3
5 Oligonucleotides Market Size by Type
5.1 Global Oligonucleotides Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Oligonucleotides Revenue by Type (2020-2031)
5.3 Global Oligonucleotides Revenue Market Share by Type (2020-2031)
6 Oligonucleotides Market Size by Application
6.1 Global Oligonucleotides Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Oligonucleotides Revenue by Application (2020-2031)
6.3 Global Oligonucleotides Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Agilent
7.1.1 Agilent Comapny Information
7.1.2 Agilent Business Overview
7.1.3 Agilent Oligonucleotides Revenue and Gross Margin (2020-2025)
7.1.4 Agilent Oligonucleotides Product Portfolio
7.1.5 Agilent Recent Developments
7.2 BBI Life Sciences
7.2.1 BBI Life Sciences Comapny Information
7.2.2 BBI Life Sciences Business Overview
7.2.3 BBI Life Sciences Oligonucleotides Revenue and Gross Margin (2020-2025)
7.2.4 BBI Life Sciences Oligonucleotides Product Portfolio
7.2.5 BBI Life Sciences Recent Developments
7.3 Creative Biogene
7.3.1 Creative Biogene Comapny Information
7.3.2 Creative Biogene Business Overview
7.3.3 Creative Biogene Oligonucleotides Revenue and Gross Margin (2020-2025)
7.3.4 Creative Biogene Oligonucleotides Product Portfolio
7.3.5 Creative Biogene Recent Developments
7.4 Eurofins Genomics
7.4.1 Eurofins Genomics Comapny Information
7.4.2 Eurofins Genomics Business Overview
7.4.3 Eurofins Genomics Oligonucleotides Revenue and Gross Margin (2020-2025)
7.4.4 Eurofins Genomics Oligonucleotides Product Portfolio
7.4.5 Eurofins Genomics Recent Developments
7.5 Eurogentec S.A
7.5.1 Eurogentec S.A Comapny Information
7.5.2 Eurogentec S.A Business Overview
7.5.3 Eurogentec S.A Oligonucleotides Revenue and Gross Margin (2020-2025)
7.5.4 Eurogentec S.A Oligonucleotides Product Portfolio
7.5.5 Eurogentec S.A Recent Developments
7.6 GeneDesign
7.6.1 GeneDesign Comapny Information
7.6.2 GeneDesign Business Overview
7.6.3 GeneDesign Oligonucleotides Revenue and Gross Margin (2020-2025)
7.6.4 GeneDesign Oligonucleotides Product Portfolio
7.6.5 GeneDesign Recent Developments
7.7 General Biosystems
7.7.1 General Biosystems Comapny Information
7.7.2 General Biosystems Business Overview
7.7.3 General Biosystems Oligonucleotides Revenue and Gross Margin (2020-2025)
7.7.4 General Biosystems Oligonucleotides Product Portfolio
7.7.5 General Biosystems Recent Developments
7.8 GenScript
7.8.1 GenScript Comapny Information
7.8.2 GenScript Business Overview
7.8.3 GenScript Oligonucleotides Revenue and Gross Margin (2020-2025)
7.8.4 GenScript Oligonucleotides Product Portfolio
7.8.5 GenScript Recent Developments
7.9 Integrated DNA Technologies
7.9.1 Integrated DNA Technologies Comapny Information
7.9.2 Integrated DNA Technologies Business Overview
7.9.3 Integrated DNA Technologies Oligonucleotides Revenue and Gross Margin (2020-2025)
7.9.4 Integrated DNA Technologies Oligonucleotides Product Portfolio
7.9.5 Integrated DNA Technologies Recent Developments
7.10 L.G.C Biosearch Technologies
7.10.1 L.G.C Biosearch Technologies Comapny Information
7.10.2 L.G.C Biosearch Technologies Business Overview
7.10.3 L.G.C Biosearch Technologies Oligonucleotides Revenue and Gross Margin (2020-2025)
7.10.4 L.G.C Biosearch Technologies Oligonucleotides Product Portfolio
7.10.5 L.G.C Biosearch Technologies Recent Developments
7.11 LC Sciences
7.11.1 LC Sciences Comapny Information
7.11.2 LC Sciences Business Overview
7.11.3 LC Sciences Oligonucleotides Revenue and Gross Margin (2020-2025)
7.11.4 LC Sciences Oligonucleotides Product Portfolio
7.11.5 LC Sciences Recent Developments
7.12 Nitto Denko Avecia Inc
7.12.1 Nitto Denko Avecia Inc Comapny Information
7.12.2 Nitto Denko Avecia Inc Business Overview
7.12.3 Nitto Denko Avecia Inc Oligonucleotides Revenue and Gross Margin (2020-2025)
7.12.4 Nitto Denko Avecia Inc Oligonucleotides Product Portfolio
7.12.5 Nitto Denko Avecia Inc Recent Developments
7.13 SGS DNA
7.13.1 SGS DNA Comapny Information
7.13.2 SGS DNA Business Overview
7.13.3 SGS DNA Oligonucleotides Revenue and Gross Margin (2020-2025)
7.13.4 SGS DNA Oligonucleotides Product Portfolio
7.13.5 SGS DNA Recent Developments
7.14 Sigma-aldrich
7.14.1 Sigma-aldrich Comapny Information
7.14.2 Sigma-aldrich Business Overview
7.14.3 Sigma-aldrich Oligonucleotides Revenue and Gross Margin (2020-2025)
7.14.4 Sigma-aldrich Oligonucleotides Product Portfolio
7.14.5 Sigma-aldrich Recent Developments
7.15 TriLink BioTechnologies
7.15.1 TriLink BioTechnologies Comapny Information
7.15.2 TriLink BioTechnologies Business Overview
7.15.3 TriLink BioTechnologies Oligonucleotides Revenue and Gross Margin (2020-2025)
7.15.4 TriLink BioTechnologies Oligonucleotides Product Portfolio
7.15.5 TriLink BioTechnologies Recent Developments
7.16 Twist Bioscience
7.16.1 Twist Bioscience Comapny Information
7.16.2 Twist Bioscience Business Overview
7.16.3 Twist Bioscience Oligonucleotides Revenue and Gross Margin (2020-2025)
7.16.4 Twist Bioscience Oligonucleotides Product Portfolio
7.16.5 Twist Bioscience Recent Developments
8 North America
8.1 North America Oligonucleotides Revenue (2020-2031)
8.2 North America Oligonucleotides Revenue by Type (2020-2031)
8.2.1 North America Oligonucleotides Revenue by Type (2020-2025)
8.2.2 North America Oligonucleotides Revenue by Type (2026-2031)
8.3 North America Oligonucleotides Revenue Share by Type (2020-2031)
8.4 North America Oligonucleotides Revenue by Application (2020-2031)
8.4.1 North America Oligonucleotides Revenue by Application (2020-2025)
8.4.2 North America Oligonucleotides Revenue by Application (2026-2031)
8.5 North America Oligonucleotides Revenue Share by Application (2020-2031)
8.6 North America Oligonucleotides Revenue by Country
8.6.1 North America Oligonucleotides Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Oligonucleotides Revenue by Country (2020-2025)
8.6.3 North America Oligonucleotides Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Oligonucleotides Revenue (2020-2031)
9.2 Europe Oligonucleotides Revenue by Type (2020-2031)
9.2.1 Europe Oligonucleotides Revenue by Type (2020-2025)
9.2.2 Europe Oligonucleotides Revenue by Type (2026-2031)
9.3 Europe Oligonucleotides Revenue Share by Type (2020-2031)
9.4 Europe Oligonucleotides Revenue by Application (2020-2031)
9.4.1 Europe Oligonucleotides Revenue by Application (2020-2025)
9.4.2 Europe Oligonucleotides Revenue by Application (2026-2031)
9.5 Europe Oligonucleotides Revenue Share by Application (2020-2031)
9.6 Europe Oligonucleotides Revenue by Country
9.6.1 Europe Oligonucleotides Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Oligonucleotides Revenue by Country (2020-2025)
9.6.3 Europe Oligonucleotides Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Netherlands
9.6.9 Nordic Countries
10 China
10.1 China Oligonucleotides Revenue (2020-2031)
10.2 China Oligonucleotides Revenue by Type (2020-2031)
10.2.1 China Oligonucleotides Revenue by Type (2020-2025)
10.2.2 China Oligonucleotides Revenue by Type (2026-2031)
10.3 China Oligonucleotides Revenue Share by Type (2020-2031)
10.4 China Oligonucleotides Revenue by Application (2020-2031)
10.4.1 China Oligonucleotides Revenue by Application (2020-2025)
10.4.2 China Oligonucleotides Revenue by Application (2026-2031)
10.5 China Oligonucleotides Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Oligonucleotides Revenue (2020-2031)
11.2 Asia Oligonucleotides Revenue by Type (2020-2031)
11.2.1 Asia Oligonucleotides Revenue by Type (2020-2025)
11.2.2 Asia Oligonucleotides Revenue by Type (2026-2031)
11.3 Asia Oligonucleotides Revenue Share by Type (2020-2031)
11.4 Asia Oligonucleotides Revenue by Application (2020-2031)
11.4.1 Asia Oligonucleotides Revenue by Application (2020-2025)
11.4.2 Asia Oligonucleotides Revenue by Application (2026-2031)
11.5 Asia Oligonucleotides Revenue Share by Application (2020-2031)
11.6 Asia Oligonucleotides Revenue by Country
11.6.1 Asia Oligonucleotides Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Oligonucleotides Revenue by Country (2020-2025)
11.6.3 Asia Oligonucleotides Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Oligonucleotides Revenue (2020-2031)
12.2 SAMEA Oligonucleotides Revenue by Type (2020-2031)
12.2.1 SAMEA Oligonucleotides Revenue by Type (2020-2025)
12.2.2 SAMEA Oligonucleotides Revenue by Type (2026-2031)
12.3 SAMEA Oligonucleotides Revenue Share by Type (2020-2031)
12.4 SAMEA Oligonucleotides Revenue by Application (2020-2031)
12.4.1 SAMEA Oligonucleotides Revenue by Application (2020-2025)
12.4.2 SAMEA Oligonucleotides Revenue by Application (2026-2031)
12.5 SAMEA Oligonucleotides Revenue Share by Application (2020-2031)
12.6 SAMEA Oligonucleotides Revenue by Country
12.6.1 SAMEA Oligonucleotides Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Oligonucleotides Revenue by Country (2020-2025)
12.6.3 SAMEA Oligonucleotides Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.